Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and…
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3…